Emerging Markets Report: The Rich Get Richer
Receive instant alerts when news about your stocks is available. Claim your 1-week free trial for StreetInsider Premium here.
ORLANDO, Florida, April 26, 2021 (GLOBE NEWSWIRE) – The bestselling news from Core One Labs Inc. (CSE: COOL) (OTC ROSE: CLABF) (FRA: LD62) (WKN: A2P8K3) last weekend. As you will recall, Core One is a life science biotechnology research and development company focused on promoting psychedelic drugs to the market.
The company already has an impressive footprint in the rapidly expanding psychedelic treatment category with new methods of delivering drugs, therapies and more.
More specifically, the company has developed a proprietary patent pending technique to create pharmaceutical grade psilocybin at a fraction of the cost. That alone could be a game-changer.
But Saturday’s news about signing a letter of intent Acquiring another company with a fantastic portfolio of psychedelic-based pharmaceuticals could take Core One Labs to the next level.
According to the statement, Core One Labs signed a letter of intent to acquire all of the outstanding shares of Akome Biotech Ltd. Akome is a developer of psychedelic-based pharmaceuticals for rare diseases and mental disorders targeting the treatments of cluster headaches (CH), Alzheimer’s disease (AD) and depression.
Obviously, there are significant potential market opportunities for the treatment of these diseases. The global Alzheimer’s disease therapies market alone is expected to reach $ 13.57 billion by 2027, up from $ 7.42 billion in 2019, with a substantial CAGR of 9.2% over the period. forecast.
We also appreciate the fact that Akome Founder and CEO Ms. Fadia Saad, who holds five patents and has over 25 years of experience in developing products and businesses in the life sciences industry, is join his team.
Joel Shacker, CEO of Core One Labs, confirms as such, stating: “The Akome acquisition will broaden and accelerate several new avenues of investigation and the overall growth potential of our company. New formulations and access to such an experienced team provide a unique opportunity to create shareholder value in this exciting industry. “
Again, this is still a letter of intent and an ink-is-dry deal has yet to be struck.
About the Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants with years of experience. Our network consists of stock brokers, investment bankers, fund managers and institutions that actively seek opportunities in the micro and small cap equity markets.
For more informative reports like this, please subscribe to http://www.emergingmarketsllc.com/newsletter.php
Must read OTC Markets / SEC Policy on Equity Promotion and Investor Protection
Section 17 (b) of the Securities Act of 1933 requires that any person who uses the mails to publish, advertise or circulate any publication or communication describing a security in exchange for consideration received or to be received directly or indirectly of an issuer, underwriter or broker must fully disclose the type of consideration (i.e. cash, bonus shares, restricted shares, stock options, warrants ) and the precise amount of the consideration. As such, EMC has received the following compensation and / or has entered into an agreement to receive some compensation in the future, as described below.
We can buy securities of the profiled company before their securities are publicly traded, which we can then publicly sell before, during or after our news release, and make a profit. EMC does not verify or approve any medical claims for any of its corporate clients.
EMC is contracted to receive $ 300,000 from Core One Lab, Inc. for various marketing services, including this report. EMC does not independently verify any content related to this editorial.
Source: Core One Labs Inc. and Emerging Markets Consulting, LLC.